Issue

  • Issue: 
    10

    G reyhounds are subject to the development of painful digital pad lesions. These lesions have the appearance of a fibrous scar tissue and have been termed corns.1–3 In essence, they are callus-like lesions. There are several theories as to the cause of these lesions. One theory is that cuts or punctures result in scar tissue accumulation.2,3 Related to this is the theory of the presence of a small foreign body in the pad. This results in accumulation of scar tissue at the lesion site, ending in a thickened hard corn as the body attempts to isolate the foreign bo

  • Issue: 
    10

    T he following article by Swaim, et al., (Pressure reduction effects of subdermal silicone block gel particle implantation: A preliminary study) is the third article to be published by WOUNDS as part of its Veterinary Wounds section and, once again, gives insight into the commonality of etiology and management of wounds frequently experienced by human patients and other animal species.
    On this occasion, the authors investigate a hypothesis that silicone particles, when inserted under a distal interphalangeal joint in a hound, with the paw subsequently being nonweightbearing f

  • Issue: 
    10

    Gladase™-C Debriding, Deodorizing, and Healing Ointment Now Available From Smith & Nephew

    Smith & Nephew Wound Management announces the launch of Gladase-C (papain-urea-chlorophyllin copper complex sodium), an enzymatic debriding, deodorizing, and healing ointment. Gladase-C is indicated for treatment of acute and chronic lesions, such as varicose, diabetic, and decubitus ulcers, burns, postoperative wounds, pilonidal cyst wounds, carbuncles, and miscellaneous traumatic or infected wounds. The product is continuously applied throughout the treatment period to remove necrotic tissue and l

  • Issue: 
    10

    Barrier Therapeutics and Healthpoint to Establish Sales and Distribution Agreement for Zimycan™

    Healthpoint and Barrier Therapeutics, Inc., a biopharmaceutical company that develops dermatology products, announce a product development and marketing agreement for Zimycan™, Barrier’s antifungal ointment. The topical petrolatum-based antifungal agent contains a 0.25-percent miconazole nitrate and zinc oxide. The ointment is for the treatment of infants with Candida-associated diaper dermatitis, an inflammatory disease in which an infant’s diaper rash is complicated with an infection c

  • Issue: 
    10

    October, 2004

    Dear Readers:

    In the Evidence Corner, Dr. Laura Bolton provides an excellent summary of hypersensitivity reactions and goes on to review two articles relevant to sensitization and sensitizing agents to consider in the leg ulcer patient. The first article by Machet, et al., (A high prevalence of sensitization still persists in leg ulcer patients: A retrospective series of 106 patients tested between 2001 and 2002 and a meta-analysis of 1975–2003 data) reported that sensitization prevalence in leg ulcer patients over the period of 1975 to 1990 was 64 percent

  • Issue: 
    10

    V enous leg ulcers are skin disorders of the lower leg that do not heal spontaneously caused by chronic venous insufficiency. They affect at least 0.2 percent of the population in the developed world,1,2 and their prevalence increases considerably with age, affecting about two percent of the population over the age of 80. Treatment of venous ulcers aims to ensure healing of the wound and prevention of recurrence. Compression, either alone or combined with surgery, is considered the principal treatment for venous ulcers and takes priority over local wound treatment. Today, short- an

Ostomy Wound Management

Press Release

ConvaTec and Boehringer Technologies Announce License Agreement


ConvaTec Acquires Exclusive Worldwide Rights for a Negative Pressure Wound Therapy System

SKILLMAN, NJ (December 18, 2008) — ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute Boehringer’s Engenex® Negative Pressure Wound Therapy (NPWT) System incorporating Bio-Dome™ Interface Technology.


WOUNDS News Wire

CME Showcase

"Diabetic Peripheral Neuropathy"

Upcoming Accredited Webcast

Release Date: December 22, 2008

Expiration Date: December 22, 2009

This activity is supported by an educational grant from PamLabs.
This activity is sponsored by the North American Center For Continuing Medical Education (NACCME).

To register for this Webcast, visit www.naccme.com/program/n-558/


"Current Concepts In Healing Chronic Diabetic Foot Ulcerations"

Upcoming Live Accredited Webcast with Q&A Noon to 1 p.m. EDT January 20, 2009

Rebroadcasts

7:30-8:30 p.m. EDT
January 27, 2009

3-4 p.m. EDT
January 28, 2009

This activity is supported by an educational grant from Advanced Biohealing.
This activity is sponsored by the North American Center For Continuing Medical Education (NACCME).

To register for this Webcast, visit www.naccme.com/program/n-550/


MRSA And Diabetic Foot Wounds: Where Do We Go From Here?
Accredited Webcast Archive Version available now. This activity is supported by an educational grant from Pfizer. This activity is sponsored by the North American Center For Continuing Medical Education (NACCME).

 

PERIPHERAL ARTERIAL DISEASE (PAD) AND CRITICAL LIMB ISCHEMIA (CLI): Managing Vascular and Wound Healing Challenges with Current and Emerging Technologies
Archived Accredited Webcast with Q&A:
This activity is supported by an educational grant from Baxter Healthcare Corporation.


Maintenance Debridement: A New Look at Science and Art
Accredited Webcast with Q&A:
November 17, 2008 at 3:00pm EST
This activity is supported by an educational grant from HealthPoint Ltd.
 

REVIEW OUR OTHER
WOUND CARE BRANDS

Check out our other resources for healthcare professionals of all specialties.

  • Ostomy Wound Management
  • Todays Wound Clinic
  • Podiatry Today
  • Skin and Aging